A Phase I and Randomized, Double-Blinded Phase II Study of Nab-Paclitaxel/Gemcitabine Plus AZD1775 or Placebo in Treatment-Naive Metastatic Adenocarcinoma of the Pancreas
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 23 Oct 2019
Price : $35 *
At a glance
- Drugs Adavosertib (Primary) ; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 18 Jul 2019 Planned primary completion date changed from 1 Jun 2019 to 31 Dec 2019.
- 31 Aug 2018 Biomarkers information updated
- 08 Aug 2017 Status changed from suspended to active, no longer recruiting.